These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 36795308)

  • 1. Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors.
    Sayegh N; Yirerong J; Agarwal N; Addison D; Fradley M; Cortes J; Weintraub NL; Sayed N; Raval G; Guha A
    Curr Cardiol Rep; 2023 Apr; 25(4):269-280. PubMed ID: 36795308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia].
    Miyazaki S
    Rinsho Ketsueki; 2021; 62(8):1024-1028. PubMed ID: 34497188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Tyrosine Kinase Inhibitors and Survival and Cardiovascular Outcomes of Patients With Non-Small Cell Lung Cancer in Taiwan.
    Chang WT; Lin HW; Chang TC; Lin SH; Li YH
    JAMA Netw Open; 2023 May; 6(5):e2313824. PubMed ID: 37195663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients.
    Totzeck M; Mincu RI; Mrotzek S; Schadendorf D; Rassaf T
    Eur J Prev Cardiol; 2018 Mar; 25(5):482-494. PubMed ID: 29376753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
    Lee N; Lee JL; Lee JY
    Target Oncol; 2023 Mar; 18(2):247-255. PubMed ID: 36826462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
    Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
    Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
    Furuya-Kanamori L; Doi SA; Onitilo A; Akhtar S
    Expert Opin Drug Saf; 2020 Feb; 19(2):223-228. PubMed ID: 31698959
    [No Abstract]   [Full Text] [Related]  

  • 9. Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors.
    Weatherald J; Bondeelle L; Chaumais MC; Guignabert C; Savale L; Jaïs X; Sitbon O; Rousselot P; Humbert M; Bergeron A; Montani D
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32527740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).
    Shah RR; Morganroth J; Shah DR
    Drug Saf; 2013 May; 36(5):295-316. PubMed ID: 23620167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors.
    Fleming MR; Xiao L; Jackson KD; Beckman JA; Barac A; Moslehi JJ
    Circ Res; 2021 Jun; 128(12):1973-1987. PubMed ID: 34110908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study.
    Yu Y; Wang Y; Wu L; Xu X; Zhou H; Wang Q; Zhou J
    Medicine (Baltimore); 2021 Feb; 100(5):e23712. PubMed ID: 33592829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.
    Lenihan DJ; Kowey PR
    Oncologist; 2013; 18(8):900-8. PubMed ID: 23918069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
    Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
    J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors.
    Hussain S; Mursal M; Verma G; Hasan SM; Khan MF
    Eur J Pharmacol; 2024 May; 970():176484. PubMed ID: 38467235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary toxicities of tyrosine kinase inhibitors.
    Peerzada MM; Spiro TP; Daw HA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):824-36. PubMed ID: 22252615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non-small-cell lung cancer: A PRISMA-compliant meta-analysis.
    Lv WW; Zhang JJ; Zhou XL; Song Z; Wei CM
    Medicine (Baltimore); 2019 Jun; 98(23):e15806. PubMed ID: 31169681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unveiling the Cardiotoxicity Conundrum: Navigating the Seas of Tyrosine Kinase Inhibitor Therapies.
    Ekram J; Rathore A; Avila C; Hussein R; Alomar M
    Cancer Control; 2024; 31():10732748241285755. PubMed ID: 39318033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.